<DOC>
	<DOCNO>NCT02423902</DOCNO>
	<brief_summary>This single-arm , phase Ib/II study examine safety , tolerability preliminary efficacy one cycle Ad-RTS-hIL-12 immunotherapy woman advance breast cancer pre-study SD PR completion minimum 12 week course standard first- second-line chemotherapy . The patient population include patient locally advance metastatic breast cancer subtypes .</brief_summary>
	<brief_title>A Study Ad-RTS-hIL-12 With Veledimex Subjects With Breast Cancer</brief_title>
	<detailed_description>Subjects PD CR standard chemotherapy eligible study . Following entry trial , patient go treatment holiday chemotherapy enter immunotherapy phase treatment . Continuation HER2-targeted antibody therapy permit immunotherapy phase woman HER2+ disease . Scans conduct 6 12 week start Ad-RTS-hIL-12 immunotherapy determine tumor response . Radiographic PD week 6 must confirm least 4 week later , either week 12 earlier clinically necessitate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Female , age ≥ 18 year 2 . Histologicallyconfirmed , locally advanced metastatic adenocarcinoma breast 3 . Achievement SD PR minimum 12 week prestudy first secondline standard chemotherapy 4 . Presence least 2 measurable lesion 5 . Standard treatment interrupt , except antiHER2 therapy 6 . All treatmentrelated radiationrelated toxicity resolve Grade 1 low 7 . Submission copy tumor measurement scan 8 . Life expectancy &gt; 12 week 9 . ECOG performance status 0 1 10 . Adequate bone marrow function 11 . Adequate liver function 12 . Adequate renal function 13 . Female subject male partner must agree must agree use highly reliable method birth control 14 . Able swallow oral medication 15 . Willing comply study procedures 1 . Metastatic breast cancer patient currently hormonal therapy first secondline permit 2 . Prior radiation therapy encompass &gt; 25 % bone marrow 3 . Any congenital acquire condition lead compromised ability generate immune response 4 . Immunosuppressive therapy 1 . Use systemic immunosuppressive drug 2 . Requirement continual immune suppression 5 . Major surgery within 4 week study treatment 6 . An active , second potentially lifethreatening cancer 7 . Presence brain subdural metastases 1 . Any sign and/or symptom brain metastasis must stable ≥ 4 week 2 . Radiographic stability determine compare contrastenhanced CT MRI scan screen scan obtain method least 4 week earlier 8 . Presence document history follow autoimmune condition : 1 . Inflammatory bowel disease 2 . Rheumatoid arthritis , systemic progressive sclerosis ( scleroderma ) , systemic lupus erythematosus , autoimmune vasculitis 3 . Motor neuropathy consider autoimmune origin 9 . Presence meningeal carcinomatosis 10 . Use medication induce , inhibit , substrates CYP450 3A4 11 . History evidence cardiac disease indicate follow : 1 . Congestive heart failure great NYHA Class II 2 . Unstable angina newonset angina ( begin within last 3 month ) , myocardial infarction within 6 month prior enrollment 3 . Cardiac ventricular arrhythmia require antiarrhythmic therapy 4 . Congenital long QT syndrome take drug know prolong QT interval 12 . Current use drug know risk cause torsades de pointes 13 . Evidence history thromboembolic , venous , arterial event within past 3 month 14 . Evidence history bleed diathesis coagulopathy 15. International normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) &gt; 1.5 x ULN , subject therapeutically anticoagulated . 16 . History malabsorption syndrome condition would interfere enteral absorption 17 . Presence active clinically serious infection 18 . Diagnosis infection HIV chronic infection hepatitis B C 19 . Any unstable clinically significant concurrent medical condition 20 . Pregnant breastfeed 21 . Use investigational , nonUnited States Food Drug Administration ( US FDA ) approve drug 22 . Participation clinical trial 23 . Presence condition make patient unsuitable</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>